If interested in volunteering to participate in a clinical research trial, or if you have concerns about the conduct of clinical research, please contact the Clinical Research office at (225) 215-1375, or by email at clinicalresearch@marybird.com.
Research is key to the future of cancer care. Clinical trials enhance standard cancer treatments, resulting in improved patient outcomes and survival rates.
Every patient at Mary Bird Perkins Cancer Center is evaluated for participation in a clinical trial. Those who meet the criteria to participate in clinical research receive a standard of care treatment, but with the added benefit of a trial that may enhance their outcomes.
Through a National Cancer Institute Community Oncology Research Program (NCORP) grant presented to LSU Health Sciences Centers in New Orleans and Shreveport, in collaboration with the Cancer Center, more advanced clinical trials are offered to patients statewide. This effort reaches about 80 percent of Louisiana residents, particularly minority populations, providing patients access to high-quality research studies closer to home.
The Cancer Center sponsors clinical trials to seek the safest and most effective treatments for each cancer type. Patients considering participating in one of our clinical trials will receive a thorough explanation from their doctor with information needed to make an informed decision. Physicians offer many clinical trials at any given time, including brain, breast, colorectal, head and neck, kidney, lung, melanoma, pancreas and prostate studies.
Clinical trials are research studies that involve human beings in order to test new ways to prevent, detect, diagnose or treat diseases. A drug must be part of a clinical trial before the FDA will approve it to be put on the market.
Oncology clinical trials are conducted in order to test new drugs or a new combination of drug treatments, new surgery and radiation therapies and new medical devices.
There are three ways you can sign up for a clinical trial:
For more information on clinical research trials, please fill out the form below and a team member will contact you.
Information on open clinical trials for bladder and urothelial cancers are below. If you have questions about a trial or you need more information on available trials, please fill out the form above and a team member will contact you.
Title: A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (DDGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for those Patients whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
Purpose: This phase II trial studies how well gemcitabine hydrochloride and cisplatin work in treating participants with invasive bladder urothelial cancer.
Physicians: Drs. Bryan Bienvenu, David Hanson, Kellie Schmeeckle, Daniel LaVie, Derrick Spell, William Varnado, James Carinder, Jack Saux, Robert Fields, Katherine Castle, Maurice King, Charles Wood, Jingya Wang, Jeffery Long, Andrew Elson, Robert Gamble, Janeiro Valle Goffin, and Sukesh Manthri
Offered in: Baton Rouge, Covington, Houma
Title: PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozatinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGrEE]
Purpose: This phase III trial studies how well Nivolumab and Ipilimumab, followed by Nivolumab versus Cabozatinib and Nivolumab, work in treating patients with renal cell cancer that is untreated and has spread to other parts of the body.
Physicians: Drs. Bryan Bienvenu, David Hanson, Kellie Schmeeckle, Daniel LaVie, Derrick Spell, William Varnado, James Carinder, Jack Saux, Robert Gamble, Janeiro Valle Goffin, and Sukesh Manthri
Offered in: Baton Rouge, Covington, Houma
Information on open clinical trials for brain cancers are below. If you have questions about a trial or you need more information on available trials, please fill out the form above and a team member will contact you.
Title: A Pivotal Randomized, Open –Label Study of Optune (TTFIELDS, 200KHZ) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
Purpose: To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and Temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and Temozolomide alone. In both arms, Optune® and maintenance Temozolomide are continued following radiation therapy.
Physicians: Dr. Jon D. Olson
Offered in: Baton Rouge
Information on open clinical trials for breast cancers are below. If you have questions about a trial or you need more information on available trials, please fill out the form above and a team member will contact you.
Title: Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) For Low Risk DCIS: A Phase III Prospective Randomized Trial
Purpose: This study looks at the risks and benefits of active monitoring (AM) compared to surgery in the setting of a pragmatic prospective randomized trial for low risk DCIS.
Physicians: Dr. Mindy Bowie
Offered in: Baton Rouge
Title: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Purpose: This phase III trial studies how well Carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body.
Physicians: Drs. Bryan Bienvenu, David Hanson, Kellie Schmeeckle, Daniel LaVie, William Varnado and Derrick Spell
Offered in: Baton Rouge
Title: Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer
Purpose: This randomized phase III trial studies digital tomosynthesis mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening and may help reduce the need for additional imaging or treatment.
Physicians: Dr. James Ruiz
Offered in: Baton Rouge (Woman’s Hospital)
There are currently no active carcinoid clinical trials. Please check back as we are continuously opening new studies.
If you have questions about a trial or you need more information on available trials, please fill out the form above and a team member will contact you.
Information on open clinical trials for colorectal cancers are below. If you have questions about a trial or you need more information on available trials, please fill out the form above and a team member will contact you.
Title: Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
Purpose: This phase II/III trial studies how well circulating tumor deoxyribonucleic acid (ctDNA) testing in the blood works in predicting treatment for patients with stage IIA colon cancer after surgery.
Physicians: Drs. Bryan Bienvenu, David Hanson, Kellie Schmeeckle, Derrick Spell, William Varnado, and Daniel LaVie
Offered in: Baton Rouge
Title: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Purpose: This phase II/III trial studies the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer.
Physicians: Drs. Bryan Bienvenu, David Hanson, Kellie Schmeeckle, Daniel LaVie, Derrick Spell, William Varnado, James Carinder, Jack Saux, Robert Fields, Katherine Castle, Maurice King, Charles Wood, Jingya Wang, Jeffery Long, Andrew Elson, Robert Gamble, Janeiro Valle Goffin, and Sukesh Manthri
Offered in: Baton Rouge, Covington, Houma
Title: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair (ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer)
Purpose: This randomized phase III trial studies combination chemotherapy and Atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair. Drugs used in combination chemotherapy, such as Oxaliplatin, Leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as Atezolizumab, may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy with Atezolizumab may work better than combination chemotherapy alone in treating patients with colon cancer.
Physicians: Drs. Bryan Bienvenu, David Hanson, Daniel LaVie, Sobia Ozair, Kellie Schmeeckle, Derrick Spell, William Varnado, James Carinder, Jack Saux, Robert Gamble, Janeiro Valle Goffin, and Sukesh Manthri
Offered in: Baton Rouge, Covington, Houma
There are no current open clinical trials for Esophageal cancers. Please check back periodically as we are always adding new trials.
If you have questions about a trial or you need more information on available trials, please fill out the form above and a team member will contact you.
There are no current open clinical trials for GI cancers. Please check back periodically as we are always adding new trials.
If you have questions about a trial or you need more information on available trials, please fill out the form above and a team member will contact you.
Information on open clinical trials for GYN cancers are below. If you have questions about a trial or you need more information on available trials, please fill out the form above and a team member will contact you.
Trial Number: MK-3475-A18/GOG-3047
Title: A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer(KEYNOTE-A18 / ENGOT-cx11)
Purpose: The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer.
Physicians: Dr. Patricia Braly
Offered in: Covington
Title: A Phase III Randomized, Placebo – Controlled Study of Pembrolizumab (MK-3475, NSC #776864) IN Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVE or Recurrent Endometrial Cancer
Purpose: This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back (recurrent).
Physicians: Drs. David S. Hanson, Kellie D. Schmeeckle, Derrick W. Spell, William Varnado
Offered in: Baton Rouge (Breast & GYN Cancer Pavilion)
Title: A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma (FLORA-5)
Purpose: To compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of patients with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.
Physicians: Dr. Patricia Braly
Offered in: Covington
Title: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (PROFECTA-II)
Purpose: Afuresertib is an AKT inhibitor, a new class of agents under development that may provide physicians with a new clinical option to control platinum resistant ovarian cancer (PROC) progression. Afuresertib plus chemotherapy has demonstrated anti-tumor efficacy and an acceptable safety profile in patients with PROC in a published Phase I/II study. Therefore, the combination of afuresertib plus weekly paclitaxel could represent a clinically meaningful step forward in the clinical management of these difficult-to-treat patients with PROC.
Physicians: Dr. Patricia Braly
Offered in: Covington
Title: A phase II, single arm study of Mirvetuximab Soravtansine in recurrent platinum-sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression
Purpose: PICCOLO (IMGN853-0419) is a Phase 2 multicenter, open label study designed to evaluate the safety and efficacy of Mirvetuximab Soravtansine in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Physicians: Dr. Patricia Braly
Offered in: Covington
Trial Number: AVB500-OC-004/GOG-3059
Title: A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer. (AXLerate-OC)
Purpose: This is a randomize, double-blind Phase 3 study to compare the efficacy and safety of AVB-S6-500 in combination with paclitaxel (Pac) versus placebo in combination with Pac in patients with platinum resistant recurrent ovarian cancer.
Physicians: Dr. Patricia Braly
Offered in: Covington
Title:A Phase 2 Clinical Study of TJ004309 in Combination with Atezolizumab (TECENTRIQ(r)) in Patients with Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors.
Purpose: This is a multicenter, open label, Phase 2 study of TJ004309 in combination with atezolizumab in patients with advanced or metastatic solid tumors
Physicians: Dr. Patricia Braly
Offered in: Covington
Title: A Phase 2b, Open-Label, Single-Arm, Multi-Center Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrent or Persistent Uterine Serous Carcinoma (ADAGIO)
Purpose: This Phase 2b study aims to evaluate the efficacy and safety of Adavosertib, an inhibitor of the tyrosine kinase WEE1, in subjects with recurrent or persistent uterine serous carcinoma (USC) who have previously received at least 1 prior platinum-based chemotherapy regimen for the management of USC.
Physicians: Dr. Patricia Braly
Offered in: Covington
Information on open clinical trials for head and neck cancers are below. If you have questions about a trial or you need more information on available trials, please fill out the form above and a team member will contact you.
Title:A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCC
Purpose: This phase II/III trials studies whether maintenance immunotherapy (Nivolumab) following definitive treatment with radiation and chemotherapy (Cisplatin) result in significant improvement in overall survival (time being alive) and progression-free survival (time being alive without cancer) for patients with intermediate risk human papillomavirus (HPV) positive oropharynx cancer (throat cancer) that has spread to nearby tissue or lymph nodes.
Physicians: Drs. Bryan Bienvenu, Daniel LaVie, David Hanson, Kellie Schmeeckle, Derrick Spell, and William Varnado
Offered in: Baton Rouge
There are currently no active liver clinical trials. Please check back as we are continuously opening new studies.
If you have questions about a trial or you need more information on available trials, please fill out the form above and a team member will contact you.
Information on open clinical trials for lung cancers are below.
If you have questions about a trial or you need more information on available trials, please fill out the form above and a team member will contact you.
Title: A Randomized Phase III Trial od Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Purpose: This trial studies how well atezolizumab added to the usual radiation therapy works in treating patients with stage I-IIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as Atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Physicians: Drs. Bryan Bienvenu, David Hanson, Kos Kovtun, Kellie Schmeeckle, Daniel LaVie, Derrick Spell, William Varnado, James Carinder, Jack Saux, Robert Gamble, Janeiro Valle Goffin, and Sukesh Manthri
Offered in: Baton Rouge, Covington, Houma
Title: A Randomized Phase II Trial of Cabozantinib and Cabozantinib plus Nivolumab Versus Standard Chemotherapy in Patient with Previously Treated Non-Squamous NSCLC
Purpose: This phase II trial compares Cabozantinib alone and the combination of Cabozantinib and Nivolumab to standard chemotherapy in the treatment of patients with non-squamous non-small cell lung cancer (NSCLC). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Physicians: Drs. Bryan Bienvenu, David Hanson, Kellie Schmeeckle, Daniel LaVie, Derrick Spell, William Varnado, James Carinder, Jack Saux, Robert Gamble, Janeiro Valle Goffin, and Sukesh Manthri
Offered in: Baton Rouge, Covington, Houma
Title: Limited Stage Small Cell Lung Cancer (LS-SCLC): Phase II/III Randomized Study of Chemoradiation versus Chemoradiation Plus Atezolizumab
Purpose: This phase II/III trial studies how well chemotherapy and radiation therapy (chemoradiation) with or without atezolizumab works in treating patients with limited stage small cell lung cancer.
Physicians: Drs. Bryan Bienvenu, David Hanson, Kellie Schmeeckle, Daniel LaVie, Derrick Spell, William Varnado, James Carinder, Jack Saux, Robert Fields, Katherine Castle, Maurice King, Charles Wood, Jingya Wang, Jeffery Long, Kos Kovtun, Andrew Elson, Robert Gamble, Janeiro Valle Goffin, and Sukesh Manthri
Offered in: Baton Rouge, Covington, Houma
Title: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Purpose: This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient’s tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Physicians: Drs. Bryan Bienvenu, David Hanson, Daniel LaVie, Kellie Schmeeckle, Derrick Spell, William Varnado, James Carinder, Jack Saux, Robert Gamble, Janeiro Valle Goffin, and Sukesh Manthri
Offered in: Baton Rouge, Covington, and Houma.
Title: Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC ALCHEMIST CHEMO-IO
Purpose: This phase III ALCHEMIST trial compares the addition of Pembrolizumab to usual chemotherapy versus usual chemotherapy for the treatment of stage IB, II, or IIIA non-small cell lung cancer that has been removed by surgery.
Physicians: Drs. Bryan Bienvenu, David Hanson, Kellie Schmeeckle, Daniel LaVie, Derrick Spell, William Varnado, James Carinder, Jack Saux, Robert Fields, Katherine Castle, Maurice King, Charles Wood, Jingya Wang, Kos Kovtun, Jeffery Long, Andrew Elson, Robert Gamble, Janeiro Valle Goffin, and Sukesh Manthri
Offered in: Baton Rouge, Covington, and Houma.
Title: Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or Fewer Brain Metastases from Small Cell Lung Cancer
Purpose: Determine whether stereotactic radiosurgery (SRS) relative to whole brain radiotherapy with hippocampal avoidance (HA-WBRT) plus memantine for brain metastases from small cell lung cancer (SCLC) prevents cognitive function failure as measured by cognitive decline on a battery of tests.
Physicians: Drs. Bryan Bienvenu, David Hanson, Daniel LaVie, Kellie Schmeeckle, Derrick Spell, William Varnado, James Carinder, Jack Saux, Robert Gamble, Janeiro Valle Goffin, and Sukesh Manthri
Offered in: Baton Rouge, Covington, Houma
There are currently no open clinical trials for lymphoma cancers. Please check back as we are continuously opening new studies.
If you have questions about a trial or you need more information on available trials, please fill out the form above and a team member will contact you.
Information on open clinical trials for multiple sites/disease are below. If you have questions about a trial or you need more information on available trials, please fill out the form above and a team member will contact you.
Title: Duloxetine to Prevent Oxaliplatin – Induced Chemotherapy – Induced Peripheral Neuropathy: A Randomized, Double – Blind, Placebo – Controlled Phase II to Phase III Study
Purpose: This phase II/III trial studies the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with Oxaliplatin in patients with stage II-III colorectal cancer.
Physicians: Drs. Bryan Bienvenu, David Hanson, Kellie Schmeeckle, Daniel LaVie, Derrick Spell, and William Varnado
Offered in: Baton Rouge
Title: Molecular Analysis for Therapy Choice (MATCH)
Purpose: This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients’ tumor cells.
Physicians: Drs. Bryan Bienvenu, David Hanson, Kellie Schmeeckle, Daniel LaVie, Derrick Spell, Maurice King, Charles Wood, Jingya Wang, Jeffery Long, Andrew Elson, Robert Gamble, Janeiro Valle Goffin, and Sukesh Manthri
Offered in: Baton Rouge, Covington, Houma
Trial Number: DCP-001
Title: Use of Clinical Trial Screening Selection Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program
Purpose: The objectives of this study are:
1) Implement a screening tool in NCORP to collect broader demographic and clinical data to generate hypothesis and research questions in the following areas of research: cancer screening, cancer prevention, symptom science, cancer care disparities, comparative effectiveness and cancer care delivery research.
2) Collect expanded demographic and clinical data (e.g., SES, co-morbidities, method of diagnosis) across the NCORP network to help identify and best characterize patients that are screened but not enrolled and for patients that participate in NCI trials, to understand how these variables may impact outcomes.
3) Enhance an understanding of site- specific and trial-specific accrual barriers that will inform the development of effective strategies to improve accrual, particularly for minority and underserved populations.
4) Provide data for internal and external evaluation of NCORP’s first RFA cycle and reissuance.
Physicians: Drs. Bryan Bienvenu, David Hanson, Kellie Schmeeckle, Daniel LaVie, Derrick Spell, Kos Kovtun, Jack Saux, Robert Fields, Katherine Castle, Maurice King, Charles Wood, Jingya Wang, Jeffery Long, Andrew Elson, Robert Gamble, Janeiro Valle Goffin, and Sukesh Manthri
Offered in: Baton Rouge, Covington, and Houma.
Trial Number: URCC-21038
Title: Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
Purpose: This study compares treatment outcomes between patients of African American/Black (AA) ancestry and European American/White (EA) ancestry currently receiving immune checkpoint inhibitor treatment. Collecting samples of blood and saliva and health and treatment information from racially diverse patients receiving immune checkpoint inhibitor treatment over time may help doctors better understand health care disparities among all cancer patients.
Physicians: Drs. Bryan Bienvenu, David Hanson, Kellie Schmeeckle, Daniel LaVie, William Varnado, Derrick Spell, Jack Saux, Faizan Malik, and Genevieve Maronge.
Offered in: Baton Rouge, Covington, and Houma.
Trial Number: AZD7442 (EVUSHELD)
Title: Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2 Infection in Immuno-Suppressed Cancer Patients
Purpose: The Astra-Zeneca Immuno-Suppressed Program (AISP) is designed to address whether a patient treated for cancer who receives a single-dose of Evusheld (AZD7442) 600 mg IM or IV will maintain a stable/protective effect against symptomatic SARS-CoV-2 infection including SARS-CoV-2 related hospitalization and/or SARS-CoV-2 related death up to 12 months post-baseline.
Physicians: Drs. Bryan Bienvenu, David Hanson, Kellie Schmeeckle, Daniel LaVie, William Varnado, Derrick Spell, Constance Blunt, Victor Lin, Lauren Juneja, and Sanjay Juneja
Offered in: Baton Rouge
There are currently no active multiple myeloma clinical trials. Please check back as we are continuously opening new studies.
If you have questions about a trial or you need more information on available trials, please fill out the form above and a team member will contact you.
There are currently no open clinical trials for neuroendocrine cancers. Please check back as we are continuously opening new studies.
If you have questions about a trial or you need more information on available trials, please fill out the form above and a team member will contact you.
Information on open observational clinical trials are below. If you have questions about a trial or you need more information on available trials, please fill out the form above and a team member will contact you.
Trial Number: S1912CD
Title: A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
Purpose: This clinical trial examines a financial navigation program in helping patients and their spouses understand and better manage the financial aspects of cancer care. Cancer patients and their spouses may be at high risk for financial problems because of the cost of cancer treatment.
Physicians: Drs. David Hanson, Kellie Schmeeckle, Derrick Spell, William Varnado, Brian Bienvenu, Daniel LaVie, Jack Saux, Robert Gamble, Janeiro Valle Goffin, Sukesh Manthri, Patricia Braly
Offered in: Baton Rouge, Covington, Houma
Information on our current Pancreatic cancer trials can be found below.
If you have questions about a trial or you need more information on available trials, please fill out the form above and a team member will contact you.
Title: A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment NaÏve Metastatic Pancreatic Cancer (GIANT)
Purpose: This phase II trial compares two treatment combinations: Gemcitabine Hydrochloride and Nab-Paclitaxel, or Fluorouracil, Leucovorin Calcium, and liposomal Irinotecan in older patients with pancreatic cancer that has spread to other places in the body (metastatic).
Physicians: Dr. Bryan Bienvenu, David Hanson, Kellie Schmeeckle, Daniel LaVie, Derrick Spell, William Varnado, James Carinder, Jack Saux, Robert Gamble, Janeiro Valle Goffin, and Sukesh Manthri
Offered in: Baton Rouge, Covington, Houma
Title: A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Purpose: This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable).
Physicians: Drs. Bryan Bienvenu, David Hanson, Kellie Schmeeckle, Daniel LaVie, Derrick Spell, William Varnado, Jack Saux, Robert Gamble, Janeiro Valle Goffin, and Sukesh Manthri
Offered in: Baton Rouge, Covington, Houma
Title: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Purpose: This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Physicians: Drs. Bryan Bienvenu, David Hanson, Kellie Schmeeckle, Daniel LaVie, Derrick Spell, William Varnado, and Constance Blunt
Offered in: Baton Rouge
We do not have any currently open prevention-based clinical trials other than those listed within other disease sites. Please check back as we are continuously adding new studies.
If you have questions about a trial or you need more information on available trials, please fill out the form above and a team member will contact you.
Information on open clinical trials for prostate cancers are below. If you have questions about a trial or you need more information on available trials, please fill out the form above and a team member will contact you.
Title: Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)
Purpose: The objective of this study is to examine how adenocarcinoma of the prostate treatment differentially affects African American men’s ability to work and to describe and compare changes in work ability (as measured through self-reported global work ability item) reported by African American and white adenocarcinoma of the prostate survivors before treatment and 6 months after treatment completion.
Physicians: Drs. Bryan Bienvenu, David Hanson, Kellie Schmeeckle, Daniel LaVie, Derrick Spell, William Varnado, James Carinder, Jack Saux, Robert Fields, Katherine Castle, Maurice King, Charles Wood, Jingya Wang, Jeffery Long, Andrew Elson, Robert Gamble, Janeiro Valle Goffin, and Sukesh Manthri
Offered in: Baton Rouge, Covington, Houma
There are currently no active renal clinical trials. Please check back as we are continuously opening new studies
If you have questions about a trial or you need more information on available trials, please fill out the form above and a team member will contact you.
We do not have any currently open clinical trials for sarcoma cancers. Please check back as we are continuously adding new studies.
If you have questions about a trial or you need more information on available trials, please fill out the form above and a team member will contact you.
We do not currently have any open clinical trials for skin cancers. Please check back as we are continuously adding new studies.
If you have questions about a trial or you need more information on available trials, please fill out the form above and a team member will contact you.
Louisiana and Gulf South residents have more options for advanced cancer treatment, thanks to a $5.6 million National Cancer Institute Community Oncology Research Program (NCORP) award. The NCORP grant continues through 2019 and focuses on conducting multi-site cancer clinical trials and cancer care delivery research studies in many Louisiana communities.
The Cancer Center is collaborating with LSU Health Sciences Center-New Orleans and LSU Health Sciences Center-Shreveport, referred to collectively as the Gulf South Minority/Underserved NCI Community Oncology Research Program (GS-MU-NCORP), to combine our strengths and experiences and bring more state-of-the-art NCI clinical trials to Louisiana cancer patients. Through this effort, we will reach about 80 percent of the state, including the most rural and urban areas where there are often great disparities in cancer care.
This grant expands cancer prevention, screening and survivorship clinical trials to improve early diagnosis and treatment as well as help patients cope with the extended process of getting back to their pre-cancer lives. Additionally, the initiative includes a multidisciplinary approach to patient care to provide the most comprehensive treatment plan for patients.
Learn More: